Your shopping cart is currently empty

PRMT7-IN-2 (A33) is a selective inhibitor of PRMT7 with an IC50 value of 0.50 μM. It causes cell cycle arrest at the G0/G1 phase, induces apoptosis, and inhibits cell growth both in vivo and in vitro. PRMT7-IN-2 reduces monomethylation levels of arginine by PRMT7, increases the expression of the epithelial marker E-cadherin, and decreases the expression of mesenchymal markers N-cadherin, Vimentin, and ZEB2.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | PRMT7-IN-2 (A33) is a selective inhibitor of PRMT7 with an IC50 value of 0.50 μM. It causes cell cycle arrest at the G0/G1 phase, induces apoptosis, and inhibits cell growth both in vivo and in vitro. PRMT7-IN-2 reduces monomethylation levels of arginine by PRMT7, increases the expression of the epithelial marker E-cadherin, and decreases the expression of mesenchymal markers N-cadherin, Vimentin, and ZEB2. |
| Molecular Weight | 473.55 |
| Formula | C25H23N5O3S |
| Cas No. | 3058094-83-7 |
| Smiles | N1=C(N=C(NC=2C=CC=3N=C(C=C(N)C3C2)C)C=4SC=CC14)C5=CC(OC)=C(OC)C(OC)=C5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.